Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.

Trial Details

NCT ID
NCT05769010
Phase
PHASE2
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • SHR-A1811
  • Pyrotinib
  • Bevacizumab
  • Adebelizumab
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Females and males ≥18 yrs old;
  • Pathologically confirmed HER2-positive or HER2-low advanced breast cancer;
  • At least one measurable intracranial lesion according to RANO-BM criteria, which had not received local treatment;
  • Without prior cranial radiation and had no indication for immediate local treatment or refuse to local treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →